Loading...
XASE
STXS
Market cap224mUSD
Dec 05, Last price  
2.41USD
1D
-0.82%
1Q
-16.90%
Jan 2017
270.83%
IPO
-67.87%
Name

Stereotaxis Inc

Chart & Performance

D1W1MN
XASE:STXS chart
P/E
P/S
8.32
EPS
Div Yield, %
Shrs. gr., 5y
6.20%
Rev. gr., 5y
-1.41%
Revenues
27m
+0.55%
15,026,39027,191,70639,298,80940,365,17351,149,55554,051,23741,987,43246,562,43438,031,08135,011,27637,674,52432,164,11631,144,10029,346,61728,902,55026,630,03535,020,86228,147,00026,771,00026,918,000
Net income
-24m
L+16.09%
-43,557,835-45,719,770-48,121,514-43,885,974-27,494,457-19,923,487-32,031,175-9,238,427-68,757,589-5,202,441-7,352,775-5,286,720-5,887,410116,756-4,232,973-6,452,892-8,437,150-19,151,000-20,713,000-24,045,000
CFO
-8m
L-7.02%
-40,986,183-38,982,881-35,713,494-28,654,503-22,308,663-18,909,745-31,569,278-12,117,658-6,331,644-9,092,143-2,528,501-6,562,754-4,674,567-2,546,582-4,616,680-3,511,772-2,945,911-8,415,000-9,139,000-8,497,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.
IPO date
Aug 12, 2004
Employees
130
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT